VA-REGULA
In addition to the clear risks, such as an increase in fraud, attracting new foreign customers presents less apparent challenges, including the absence of standardized documentation and language barriers. These are the results of a global survey conducted by Regula, a global developer of forensic devices and identity verification solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423489077/en/
Top problems businesses deal with when verifying foreign IDs, according to Regula’s survey (Graphic: Business Wire)
Key challenges for businesses
When it comes to identity verification for international customers, including a growing community of digital nomads, organizations from various industries participating in Regula’s survey tend to point out the following challenges:
- The lack of unified document standards. 41% of decision-makers in all sectors report a significant challenge due to the lack of standardized identity documents. This inconsistency affects the efficiency and speed of IDV processes. For government services, the problem seems to be even worse, since 48% of the respondents in this sphere named this issue as the main challenge.
- The increase in fraud. Identity-related fraud continues to be a major concern, affecting 40% of businesses overall. Higher impacts of fraud are observed in Banking and Financial Services (48% of respondents call it a key challenge) and Retail (44% of respondents).
- Language barriers. Complexities due to language differences are reported by 36% of businesses. For the Healthcare and Insurance industries, this is an even greater concern, with 41% and 39% of respondents correspondingly naming it among the top three challenges.
Dealing with new identity documents and facing new risks, organizations strive to pursue a high level of identity verification (IDV) security and accuracy, with every third of them expressing the need for an increase in their IDV budget by up to 20%.
"As the world is starting to pilot the concept of digital IDs, it is possible that in the foreseeable future, we will achieve a certain level of identity document standardization. That means some of the current challenges in international ID verification will likely be mitigated,” says Henry Patishman, Executive Vice President of Identity Verification Solutions at Regula. “In the meantime, both businesses and IDV providers have to concentrate on tackling fraud and language barriers. From our experience, we see that there are two effective ways of dealing with these issues: enhancing the set of document and biometric checks, with a strong emphasis on data cross-checks to spot any possible inconsistencies that may indicate fraud, and growing your own document knowledge database to be able to read any document in any language correctly.”
Major concerns for customers
In their turn, digital nomads who settle in foreign countries for short or long periods of time also face challenges related to identity verification. Predominantly, their concerns revolve around the document validity period, which has an expiry date and proof of residency, such as rental agreements or utility bills. Each of these issues is a challenge for 19% of Regula’s survey respondents.
Apart from that, 18% of digital nomads have difficulties with ID verification because of their frequent travel and changing locations, which create inconsistencies in the information provided, and potentially lead to delays or rejection in identity proofing. Another 18% of respondents feel a lack of trust and credibility from institutions due to the unconventional nature of their lifestyle and work arrangements.
As for the language barrier, 70% of digital nomads say they have encountered language difficulties in understanding the instructions during the verification process. However, only 16% of nomads cite language barriers as a top frustration during the ID verification process. At the same time, twice as many digital nomads (36%) feel frustrated because of Internet connectivity issues: majorly relying on public Wi-Fi networks, they face an increased risk of cybersecurity threats and data breaches during the verification process.
The research has also shown that only 29% of nomads are very comfortable with providing sensitive identification documents online while being in a foreign country.
To learn more about the concerns and frustrations for both businesses and digital nomads, read the full report on the survey. To find out how to cope with various difficulties during the identity verification process, please visit Regula’s solutions page and learn about the advanced technologies for document and biometric checks.
*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.
Resources:
- Blog article Identity Verification in a Globalized World -– https://regulaforensics.com/blog/identity-verification-in-nomad-era-research/
- Survey report Identity Verification in a Globalized World – https://regulaforensics.com/resources/identity-verification-for-digital-nomads-report/
- Regula Document Reader SDK – https://regulaforensics.com/products/document-reader-sdk/
- Regula Face SDK – https://regulaforensics.com/products/face-recognition-sdk/
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423489077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
